GD 134

Drug Profile

GD 134

Alternative Names: GD-134

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Griffin Discoveries
  • Class Anti-inflammatories; Eye disorder therapies; Quinazolines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic conjunctivitis

Highest Development Phases

  • Research Allergic conjunctivitis

Most Recent Events

  • 19 Jul 2016 GD 134 is available for licensing as of 19 Jul 2016. http://www.griffindiscoveries.com/
  • 19 Jul 2016 Early research in Allergic conjunctivitis in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top